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Abstract 
To evaluate seasonal trivalent inactivated influenza vaccine effectiveness (VE) in Scotland, a 
Scotland-wide linkage of patient-level primary care, hospital and virological swab data from 
3,323 swabs (pooling data over nine influenza seasons: 2000-2009) was performed. VE was 
estimated for reducing real-time polymerase chain reaction (RT-PCR) confirmed influenza 
using a test-negative study design. Vaccination was associated with a 57% (95% confidence 
intervals [CI] 31 to 73) reduction in the risk of RT-PCR confirmed influenza. VE was 60% 
(95% CI 22 to 79) for patients under 65 and clinically at-risk of serious complications from 
influenza and 19% (95% CI -104 to 68) for any individual 65 years and older. Vaccination 
was associated with substantial, sustained reductions in laboratory-confirmed influenza in the 
general population and younger patients in clinical at-risk groups. 
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Introduction 
Each year, influenza causes substantial morbidity and mortality, particularly in people aged 
65 years and older and those with underlying serious comorbidities [1]. Globally, for 
example, it is estimated that influenza is responsible for 5 million cases of severe illness and 
250,000 to 500,000 deaths per year; the 186,000 excess hospitalisations and 44,000 excess 
deaths in the United States (US) have been estimated to cost USD 87 billion (EUR 77 billion) 
per year [2-4]. Annual costs of influenza epidemics for the European Union are estimated to 
be EUR 27 billion [5]. National vaccination strategies represent a potentially important 
approach to reduce both influenza-related illness and death, hence the considerable 
investment in this preventive approach in many parts of the world. In Scotland, the influenza 
vaccination programme has been successful with high rates of uptake for targeted individuals 
such as adults aged over 65 years and those clinically at risk of serious influenza-like illness 
[6]. There is evidence of the benefits of the seasonal influenza vaccine in healthy children and 
younger adults (16 to 65 years) [7,8]. However, in populations at highest risk of developing 
influenza-UHODWHG FRPSOLFDWLRQV HJ DGXOWV(?(? years and older, people with medical 
conditions such as diabetes, heart or respiratory disease, and people with immunodeficiency), 
the populations particularly targeted by many countries’ vaccination programmes including in 
Scotland, there is a paucity of reliable estimates of efficacy from randomised controlled trials 
[9]. This is of concern, as it has been suggested that influenza vaccine is less effective in 
older people due to immunosenescence [10]. Given that influenza vaccination programmes 
now exist in most developed countries, randomised controlled trials of the vaccine are 
impractical; these are also viewed as unethical by some sections of the medical community 
[11]. Observational studies are a study design that can be used to investigate the effectiveness 
of vaccine programmes. 
Since 2005, the test-negative study design, using real-time RT-PCR testing, has become more 
commonly used for evaluating influenza vaccine effectiveness (VE) [12]. Most, however, 
have been carried out on single influenza seasons [13] and the three which have pooled data 
from multiple seasons only reported VE for limited age groups [14-16]. Building on related 
work [17,18], we undertook a data linkage study and used detailed electronic health record 
data over nine consecutive seasons 2000/01 to 2008/09 to determine VE of the trivalent 
inactivated influenza vaccine in reducing laboratory-confirmed influenza. 
 
Methods 
Study databases and population characteristics 
Almost all individuals resident in Scotland are registered with primary care, which provides a 
comprehensive array of healthcare services (free at the point of care), including prescriptions 
for medications. We used the Practice Team Information network, which covers a 5% 
representative sample of Scottish practices [19]. Using the unique Community Health Index 
(CHI) number, specific patient-level data approved for use in this project were extracted and 
then linked to the Health Protection Scotland virology dataset, which consists of all 
laboratory-confirmed cases of influenza in Scotland. Once linkage had been completed, the 
analysis file was anonymised by replacing the unique CHI number with a study identifier. 
We established key population characteristics: sex, age (0–4, 5–14, 15–44, 45–64, 65–74, 
DQG(?(? \HDUV VRFLRHconomic status (Scottish Index of Multiple Deprivation scores [20] 
H[SUHVVHGDVTXLQWLOHV(? (?PRVWGHSULYHGWR(? (?PRVWDIIOXHQWUHFHLSWRISQHXPRFRFFDODQG
influenza vaccination in the previous year, smoking status (current, ex, non, not recorded), 
urbDQUXUDOUHVLGHQFH(? (?ODUJHXUEDQWR(? (?UHPRWHUXUDOZKHWKHUDSDWLHQWZDVLQDFOLQLFDO
group at risk of serious illness from influenza (i.e. chronic respiratory disease, chronic heart 
disease, chronic kidney disease, chronic liver disease, chronic neurological disease, 
immunosuppression or diabetes), Charlson co-morbidity index [21], number of previous 
primary care consultations, prescribed drugs and hospital admissions (in the year before 1 
September). 
Study design 
In order to estimate VE derived from linked virological swab data, we carried out a test-
negative study similar to that used by I-MOVE [22], pooling data from nine influenza 
seasons (2000/01 to 2008/09). Influenza A(H1N1) subtype was dominant in 2007/8 
(A/Solomon Island/3/2006) and H3N2 subtype was dominant in 2001/2 (A/Panama/2007/99), 
2003/4 (A/Fujian/411/2002), 2006/7 (A/Wisconsin/67/05) and 2008/9 (A/Brisbane/10/2007).  
Influenza B was dominant in 2005/6 (B/Malaysia/2506/2004). Influenza A(H1N1) (A/New 
Caledonia/20/99) and influenza B (B/Beijing/184/93) were co-dominant in 2000/1. Influenza 
A(H3N2) and influenza B were co-dominant 2002/3 (A/Panama/2007/99, 
B/HongKong/330/01) and 2004/5 (A/Wellington/01/2004, B/Shanghai/361/2002). We carried 
out an individual patient-level pooled analysis and adjusted for year. The influenza season 
was defined as the period from the date of the first influenza isolate reported by Health 
Protection Scotland for each year, in or after week 40 and the date of the last influenza isolate 
before or in week 20 (during the period of peak influenza). Vaccination was used to define 
exposure status if it was given at a time point between the start of the pre-influenza season 
(i.e. 1 September) and the end of the influenza season. An individual was defined as 
vaccinated 14 days after the seasonal influenza vaccine was administered. The time period 
from the first day of the influenza season to day 14 post vaccination was defined as 
‘unexposed’ and the period from day 14 post vaccination until the end of the influenza season 
was defined as ‘exposed’. The earliest influenza season began on 26 September and the latest 
began on 25 November, and all seasons finished in May (Table 1). A protocol of the study 
methods has been previously published [23]. 
Study outcomes 
General practitioners in this study were also involved in the Health Protection Scotland 
sentinel-swabbing scheme, whereby practices are encouraged to obtain nasal or throat swabs 
from patients of all ages who have presented with symptoms suggestive of influenza. This is 
independent of whether or not the patient has been vaccinated. Each general practice is 
requested to submit five swab samples per week to the West of Scotland Specialist Virology 
Centre, Glasgow, UK for PCR testing for a range of respiratory pathogens. We also included 
results from swabbing carried out in primary and secondary care for routine diagnostic 
purposes in symptomatic patients outside the sentinel scheme. As a post-hoc sensitivity 
analysis, we excluded patients recruited from non-VHQWLQHOVRXUFHVQ(? (?DQGWKRVH
SUHVHQWLQJ V\PSWRPV OHVV WKDQ  GD\V DIWHU YDFFLQDWLRQ Q(? (?  7KH :HVW RI
Scotland Specialist Virology Centre is a World Health Organization-accredited National 
Influenza Center, which participates in the Quality Assurance programme to maintain this 
status. To calculate VE, patient swab data were linked with the unique patient identifier CHI, 
allowing characteristics of patients such as vaccination status to be established from general 
practice and hospital admission data. In 2005/06 when influenza B (B/Malaysia/2506/2004) 
was the predominant circulating virus type, tests were performed in sufficient numbers to 
estimate VE against influenza B in that season. 
The Privacy Advisory Committee of the Information Services Division, National Services 
Scotland, approved the linkage and analysis of the anonymised datasets for this project. 
Statistical methods 
A generalised additive logistic regression model [24] was fitted, adjusting for the effects of 
week during season (through a separate spline model each season) and age, sex, deprivation, 
smoking status, number of primary care and hospital consultations in the previous 12 months, 
influenza vaccination in the previous season, and being in a clinical group at risk of serious 
complications from influenza. Some of these patients did not receive the influenza vaccine; 
some received the vaccine, but after they were tested; and others had received the vaccine 
before they were tested. We therefore measured VE by comparing swabs taken after 
vaccination from individuals who were vaccinated, with swabs taken from all those who were 
not vaccinated at the time the swab was taken (people who were unvaccinated at the time of 
swab and who were then subsequently vaccinated counted as unvaccinated in our analysis as 
did people who were never vaccinated). When two doses were given we used the date of the 
first vaccine dose in our analysis. We stratified our analysis by people 65 years and older vs 
people younger than 65 years and at risk, and also tested for any heterogeneity between 
seasons. We also tested for any heterogeneity or collinearity between receipt of current and 
previous season’s influenza vaccination. 
Using data from previous studies, we estimated that with 400 swabs per year, an effectiveness 
of 20% would be detected with 79% power for our primary outcome of PCR-confirmed 
influenza (assuming that 15% of the population would be vaccinated, 30% swab-positive and 
adjusting for clustering within each primary care practice [25,26]). All statistical analysis was 
conducted using R (version 2.14.1). 
Results 
A total of 3,323 swabs were taken from 3,016 patients with influenza symptoms over the nine 
seasons (of a total registered primary care population of 1,767,705 person-seasons) and then 
tested with RT-PCR for evidence of influenza infection. Some 489 swabs (14.7%) were 
performed on individuals who were vaccinated at the time of the swab. Although all 
subgroups were represented, proportionately more young, female, and socioeconomically 
deprived patients were swabbed (Table 2). Furthermore, a large proportion of the virological 
tests (42.3%) were carried out on patients that had presented more than five times to primary 
care in the previous year. During our study, 13.9% of swabs were positive for RT-PCR-
confirmed influenza, with male patients and the socioeconomically affluent being more likely 
to test positive for influenza (Table 2). One quarter of the swabs from school-aged children 
(5–14 years) tested positive for RT-PCR-confirmed influenza. Pooled over nine seasons, VE 
for the trivalent inactivated influenza vaccine in the whole population was 57% (95% 
confidence interval (CI): 31–73) (Table 3). VE for at-risk patients under 65 years was 60% 
(95% CI: 22–DQG&,íWRIRU\HDUVDQGROGHU$OWKRXJKWKHUHZDV
YDULDELOLW\EHWZHHQVHDVRQVQRVLJQLILFDQWKHWHURJHQHLW\ZDVIRXQGS(?(?WKHUHZHUHQR
positive tests among vaccinated people in 2000/01 and the highest VE was found in season 
2007/08 (Table 4). In 2005/06 for influenza B, there were 44 positive tests in 426 
unvaccinated and three in 137 vaccinated individuals. In that season, VE against influenza B 
was 79% (95% CI: 32–96). 
When including influenza vaccination in the previous season (for all nine seasons), the 
vaccine effect in the current year was 55% (95% CI: 22–74) and there was no significant 
HIIHFW RI WKH YDFFLQDWLRQ LQ WKH SUHYLRXV \HDU 25(? (?  &, –1.52). A post-hoc 
interaction test showed a signifLFDQW S(? (? LQWHUDFWLRQ EHWZHHQ UHFHLSW RI WKH SUHYLRXV
season’s and the current season influenza vaccination and VE but no major collinearity. Table 
5 presents the VEs of three possible combinations of vaccinated or unvaccinated in the 
current or previous season (combining all the seasons studied) compared with people with no 
vaccination in either season. Significant positive VEs were found for subgroups vaccinated in 
the current and previous season and those vaccinated in the current but not the previous 
season. A non-significant positive VE was found for people vaccinated in the previous season 
but not the current. 
VE was similar to our primary analysis when excluding virological tests from non-sentinel 
sources (60%; 95% CI: 31–77) or patients with onset of symptoms less than 14 days after 
YDFFLQDWLRQ9((? (?&,–76). 
Discussion 
Our trivalent influenza VE using RT-PCR in symptomatic patients presenting over nine 
VHDVRQV ZDV VLPLODU WR WKH HIILFDF\ IRXQG LQ KHDOWK\ DGXOWV \RXQJHU WKDQ(?years in 
controlled trials (66% vs 75%) [8]. Our findings were also similar to other observational 
studies which pooled data across several seasons and estimated a VE of 61% for adults 50 
years and older [15] and 62% for 20–64 year-olds [14]. In a single season (2012/13) in which 
genetic drift of the predominant influenza A(H3N2) strain had occurred, the VE estimate for 
SHRSOH(?\HDUVDQGROGHUZDVíDJDLQVWLQIOXHQ]D$>27]. This is lower than our pooled 
estimate of 19% VE for this age group over nine seasons with different circulating strains. In 
the 2007/08 season when vaccine and circulating virus were well matched and influenza 
A/Solomon Island/3/2006 (H1N1) was the main circulating virus, our VE was higher for 
laboratory-confirmed influenza than in a US study in the same season which used a study 
design similar to ours (80% vs 52%) [28]. In the 2005/06 season when influenza 
B/Malaysia/2506/2004 was the predominant strain, our estimate of 29% was similar to a US 
study (21%) [29], but lower than reported in Canada (63%) [30]. These differences in VE are 
likely to be due to between-country variation in the distribution of vaccine types, dominant 
circulating influenza types, subtypes, and lineages, and antigenic (mis)match between 
vaccine virus and circulating virus [31]. Although there was poor precision, we found 
variations in VE over the seasons. In the two seasons when influenza A(H1N1) co-dominated 
or dominated and the vaccine was well matched (2000/01 and 2007/08, respectively), VE was 
KLJK (?80%). In 2003/04 and 2004/05 when vaccine mismatch occurred in the A(H3N2) 
component of the vaccine, VEs of 49% and 44% were found. In 2005/06 when there was 
vaccine mismatch for influenza B, a 79% VE for influenza B was found. This was similar to 
findings in a well-powered study in the same season on influenza B in England (67%; 95% 
CI: 31–85). In all other seasons, influenza A(H3N2) was the predominant influenza A 
subtype and VE varied from 22% (2006/07) to 77% (2001/02) [32].  
Our finding of an interaction, whereby prior influenza vaccination interfered with current 
vaccine effectiveness, has been described previously in a community-based study [33]. 
Similar to that study, we were limited by a relatively small number of cases and were only 
able to dichotomise prior and current season vaccination status (yes or no). However, this 
simplified approach has been criticised and a more in-depth analysis has been suggested 
which includes the number, nature and antigenic distance specified by virus mutations across 
sequential circulating variants and vaccine components [34]. This is a potential avenue for 
further work. 
Clinical data collected by these sentinel practices are of high quality (90% completeness and 
accuracy [25]) and their value for epidemiological research has been repeatedly demonstrated 
[26]. Observational studies can be used to assess the effects of healthcare interventions 
without influencing the care provided or the patients who receive it. When used in the 
assessment of vaccination programmes they therefore have high external validity and can be 
broadly generalised. Furthermore, by pooling data from nine seasons from the same 
population, we were able to generate sufficient power to provide a precise VE estimate. The 
test-negative design offers an elegant way to deal with selection bias that may arise if there is 
a strong association between vaccination status and subject recruitment. However, this design 
only measures the protection provided by the vaccine to individuals seeking medical 
attention, rather than VE against influenza, because for some persons (e.g. people with co-
morbidities and at risk of serious complications from influenza), vaccination may not truly 
prevent influenza, but may reduce illness severity, preventing death or hospitalisation or 
reducing severity below their care-seeking threshold [35]. If possible, one should therefore 
assess the likely impact of VE on disease severity [36] and the influence of non-influenza 
acute respiratory infections by restricting controls to those who tested negative for influenza 
and positive for a different respiratory pathogen (e.g. parainfluenza or respiratory syncytial 
viruses) [35,37]. Swabs from symptomatic patients outside the systematically collected subset 
were included in our study, and this may have led to some selection bias, although physicians 
swabbing in secondary care (where the majority of non-sentinel swabbing took place) were 
unlikely to know the patient’s vaccine status unless self-reported and a sensitivity analysis 
found no change to our VE estimates (but decreased their precision). However, even with the 
inclusion of these additional tests from non-sentinel sources, there was an over-representation 
of swabs from working-age adults and therefore we had lower power to measure VE among 
children and older people. There was also inadequate power to measure pooled estimates of 
VE for types or subtypes of influenza (e.g. A(H3N2), A(H1N1) and B), most individual 
seasons, patients with chronic diseases (e.g. asthma) or pregnancy (which was not included as 
a risk factor for this analysis) or for those given a second dose of the vaccine. A much larger 
study is therefore required to perform these stratified analyses. In our primary analysis, we 
considered that the vaccine effect was random over seasons rather than the seasons having 
random effect. In this pooled model we found that there was already a different intercept and 
seasonal trend each year and that this permitted more differences among the seasons 
compared with a random effects model. The random effects meta-analysis estimate was 51%, 
close to the pooled estimate reported in this paper (57%). Furthermore, treating each season 
equally gave a VE estimate of 65%. Some of the patients were found to have contributed with 
more than one swab in different seasons, with 231 people with swabs in two seasons, 27 with 
swabs in three seasons and six with swabs in more than three seasons. We therefore 
performed post-hoc sensitivity analyses using a generalised estimating equation (GEE) model 
and a clustered regression model. Both of these models were found to inflate the variance of 
the vaccine effect, but did not have a major impact on the conclusions. 
Our primary objective was to make use of the best integrated and accessible Scottish data 
available to us to evaluate a new national influenza vaccination programme introduced in 
Scotland in September 2000. During the period 2000 to 2009, seasonal influenza vaccination 
was provided to at-risk groups (at no cost to the patient) through primary care. This targeted 
approach resulted in high vaccine uptake rates of 66 to 76% in older people and 38 to 49% in 
at-risk groups [6]. We found that during the period when the programme was implemented 
(and before pandemic influenza), which included seasons with poor vaccination match and 
severe influenza, there was strong evidence for the effectiveness of vaccination in preventing 
laboratory-confirmed influenza, particularly for younger people and people susceptible to 
severe influenza-like illness. This information should reassure countries considering the 
implementation of a similar programme. However, while work is being undertaken to 
produce better vaccines and new vaccines are introduced, the continued development of a 
strong international evidence base is required to monitor the effectiveness of seasonal 
influenza vaccination programmes, particularly among subgroups of patients at risk of serious 
complications from influenza such as older people. 
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Table 1. Influenza seasons start and end dates, Scotland, 2000–09 
 
 
 
 
 
 
 
 
 
  
Year Start date End date 
2000/1 05-10-00 14-05-01 
2001/2 18-10-01 17-05-02 
2002/3 25-11-02 15-05-03 
2003/4 26-09-03 07-05-04 
2004/5 22-10-04 19-05-05 
2005/6 06-10-05 16-05-06 
2006/7 19-10-06 09-05-07 
2007/8 02-10-07 13-05-08 
2008/9 13-11-08 05-05-09 
 Table 2 Number of swabs vs laboratory-confirmed influenza, by population group, Scotland, 2000–Q(? (? 
Description Total samples  Swab positive 
(number and % of swabbed positive) 
Swab positive adjusted 
odds ratio* 
Adjusted odds ratio 
95% CI 
Gender: Female 1995  248 (12·43) 1·00  
Male 1328  214 (16·11) 1·35 1·07 to 1·69 
Age group (years): 0-4 390  60 (15·38) 1·00  
5-14 433  104 (24·02) 1·56 1·05 to 2·32 
15-44 1405  196 (13·95) 0·89 0·63 to 1·27 
45-64 741  79 (10·66) 0·71 0·47 to 1·06 
65-74 244  18 (7·38) 0·67 0·36 to 1·28 
75+ 110  5 (4·55) 0·41 0·15 to 1·13 
Deprivation quintile: 1† 961  100 (10·41) 1·00  
2 789  97 (12·29) 1·18 0·85 to 1·63 
3 735  116 (15·78) 1·55 1·13 to 2·12 
4 519  96 (18·50) 1·94 1·39 to 2·71 
5 309  51 (16·50) 1·86 1·24 to 2·79 
Influenza vaccine previous season: No 2817  426 (15·1) 1·00  
Yes 506  36 (7·1) 0·90 0·53 to 1·52 
Primary care consults: 0-2 1133  206 (18·18) 1·00  
3-4 785  103 (13·12) 0·69 0·52 to 0·92 
>5 1405  153 (10·89) 0·87 0·66 to 1·15 
Secondary care consults: 0 2728  400 (14·66) 1·00  
1-2 456  47 (10·31) 0·73 0·51 to 1·04 
>3 139  15 (10·79) 0·78 0·42 to 1·45 
* Adjusted for week during season, age, sex, previous season influenza vaccination, consultations and socioeconomic deprivation  
† Most socioeconomically deprived 
 
  
Table 3 Proportion of vaccinated by case/control status and adjusted vaccine effectiveness for laboratory-confirmed influenza, Scotland, 
2000–Q(? (? 
 
 
* Adjusted for week during season, sex, number of hospital and primary care consultations, socioeconomic deprivation and being in a clinical at-risk group 
(where appropriate)  
† All patients including clinical at-risk 
 
  
 Influenza positive (cases) Influenza negative (controls)  
Adjusted vaccination 
effectiveness (95% CI)* Age groups Vaccinated/ 
Total (N) 
Vaccinated (%) Vaccinated/ 
Total (N) 
Vaccinated (%) % total positive  
 
      
<65 years † 14/439 3·19 249/2530 9·84 14·79 66 (39 to 81) 
<65 years clinical at-risk 14/117 11·97 209/788 26·52 12·93 60  (22 to 79) 
\HDUV 13/23 56·52 222/331 67·07 6·50 19 (-104 to 68) 
All ages 27/462 5·84 471/2861 16·46 13·90 57 (31 to 73) 
Table 4 Vaccine effectiveness for laboratory-confirmed influenza and predominant circulating influenza by season, Scotland, 2000–09 
Q(? (? 
 
* Poorly matched vaccine 
  
 Influenza positive (cases) Influenza negative 
(controls) 
   
 
Seasons Vaccinated/ 
Total (N) 
Vaccinated 
(%) 
Vaccinated/ 
Total (N) 
Vaccinated 
(%) 
% total 
positive  
Adjusted 
vaccination 
effectiveness 
(95% CI)* 
Dominant types circulating  
 
2000/1 0/59 0·00 53/404 13·12 12·93 NA A/New Caledonia/20/99 (H1N1) 
B/Beijing/184/93 
 
2001/2 1/55 1·82 25/310 8·06 7·67 77 (-117 to 98) A/Panama/2007/99 (H3N2)  
2002/3 1/21 4·76 22/220 10·00 10·55 68 (-310 to 98) A/Panama/2007/99 (H3N2) 
B/HongKong/330/01 
 
2003/4 4/56 7·14 12/269 4·46 5·18 49 (-58 to 84) 340 A/Fujian/411/2002 (H3N2)*  
2004/5 5/49 10·20 60/351 17·09 19·40 44 (-66 to 81) A/Wellington/01/2004 (H3N2)* 
B/Shanghai/361/2002 
 
2005/6 6/141 4·26 52/470 11·06 10·49 29 (-109 to 76) A/California/7/2004 (H3N2)* 
B/Victoria/2/87 
 
2006/7 2/26 7·69 23/228 10·09 10·92 22 (-375 to 87) A/Wisconsin/67/05 (H3N2)  
2007/8 3/43 6·98 55/214 25·70 29·15 80 (21 to 95) A/Solomon Island/3/2006 (H1N1)  
2008/9 4/40 10·00 50/254 19·69 22·50 38 (-136 to 84) A/Brisbane/10/2007 H3N2  
Table 5: Vaccine effectiveness for the combined influenza vaccinations in the previous and current season, Scotland, for all seasons 
Q(? (? 
 
Previous season Current season  Vaccine effectiveness 95% CI P compared with 
unvaccinated in both 
seasons 
Unvaccinated Unvaccinated 0 0 to 0 NA 
Vaccinated Unvaccinated 47.6 -6.1 to 74.1 0.072 
Unvaccinated Vaccinated 85.2 51.5 to 95.5 0.002 
Vaccinated Vaccinated 50.4 15.6 to 70.8 0.010 
 
